

PSYCHOPHARMACOLOGY FUNDAMENTALS

3rd Annual Critical Issues in Child & Adolescent Mental Health Conference

Jason Schweitzer, MD, MSW
Assistant Professor, Department of Psychiatry
University of California San Diego
Friday, March 23, 2017

Introduction

- Rady Children's Hospital
- UCSD Community Psychiatry Program
- All Cases discussed herein have been de-identified


Overview

- Why do children and families seek help?
- Bio-Psycho-Social factors
- Diagnoses
- Psychopharmacology
- Cases



Overview

- Why do children, adolescents and families seek help?




Why seek help?

- Safety
 - Extra-familial
 - Intra-familial
- Family dynamics
- School
 - Success
 - Bullying




Why seek help?

- Behaviors
 - Function within family
 - Function within school




Why seek help?

- Behaviors
 - Psychological function
- Emotion regulation
- Levels of arousal




Why Seek Help?

- Pro-drome
- Psychosis
- Substance abuse
- ADHD




Diagnoses

- Translating presenting problem into diagnosis can be difficult
- Our research tends to focus on diagnoses




Diagnoses

- Depression
- PTSD
- Anxiety
- Psychosis







Depression

- 17 year old female admitted to the inpatient unit after an intentional ingestion of acetaminophen, reporting several months of sadness, hopelessness, and suicidal ideation.



Hypothetical Physiology of Depression





Course of Pediatric Depression

- Episodic (Kovacs et al, 2016)
- First episode ~ 37 weeks
- Time between episodes decreases as time progresses
- More data needed

Impact

- Quality of life
- Suicide – 6% of high school youth in San Diego reported a suicide attempt in 2009
- Self-injury – 24 % of high school youth reported self-injury
- Rates of suicide are rising
- Take overdose, suffocation and strangulation extremely seriously

General Treatment Approach

- Understand that rates of depression are common
- Make use of brief screening tool
- Make therapy referrals for all cases of depression
- SSRIs – Fluoxetine, escitalopram, sertraline

Symptoms (DSM5)

- Two weeks of LOW MOOD OR IRRITABILITY
- Or Anhedonia with ≥ 3
 - Weight loss/ poor appetite
 - Sleep problems
 - Anergia
 - Worthlessness or guilt
 - Poor concentration
 - SI

Pediatric Considerations

- Less Anhedonia
- Less psychomotor slowing

Pediatric Considerations

- Irritability
- Increased sensitivity to failure, rejection
- Physical complaints, headache, stomach ache
- Absenteeism, poor school performance
- Thoughts of / running away
- Substance use

Differential

- Bipolar disorder
- Substance Abuse
- Prodrome
- Trauma
- PMDD – Premenstrual
- Persistent Depressive Disorder

Developmental Differences

- Preschool
- Children
- Teens


Risks for Depression

- Genetics
- Physical Health
- Life events
- Family conflict
- Community or domestic violence

Risks for Depression

- Learning disorder
- Hormone changes
- Substance abuse
- Bullying
- Trauma

Treatment



Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2013.

SSRIS

- Treatment of choice for anxiety and depression
- Generally safe
- Rare adverse effects can be serious, but managed with close monitoring
 - Suicidal Ideation (Black Box), Bleeding, Electrolyte abnormalities
- In general, neither initial nor regular labs are required

SSRIS

- Therapy is essential
- Combination of CBT and SSRI can increase rate of response
 - ~ 60% with medication only to ~ 70% meds and CBT (March et al, 2004)

SSRIS

- First Line: Big Three
 - Fluoxetine
 - Escitalopram
 - Sertraline
- Return in 1-2 weeks to see if tolerating, ask about SI.
- Up-titrate
 - *Week 8 – good response or maximal dose*

Medications: SSRIS

- Second Line: A different one of the big Three
 - Fluoxetine
 - Escitalopram
 - Sertraline

Common Side Effects:

- Headache, GI upset
- Black Box Warning: Suicidal Ideation

Fluoxetine

- Fluoxetine 10 to 40 mg po daily (TADS Study; Cochrane Review)
- Statistically Sig Reduction in depressive symptoms when compared to placebo
- Highest rates of remission 23% - 57%
- FDA Approved
- Adolescents: Start at 10 mg, within 1-2 weeks increase to 20 mg, true target is remission
- School Age: Start lower 5; Use Liquid; go Slow

Escitalopram

- Escitalopram 10 to 20 mg po daily (TADS Study; Cochrane Review)
- Statistically Sig Reduction in depressive symptoms when compared to placebo
- FDA Approved
- Adolescents: Start at 5 mg, increase to 10 mg, true target is remission, increase accordingly
- School age kids go slower

Medications: SSRIS

- Lowest effective dose, target remission
- Symptomatic and tolerating? Increase
- Effect can take 3-5 Weeks per dose change
- Monitor weekly or bimonthly
 - Suicidal ideation
 - Mania or hypomania (SLEEP, personality change, etc.)

Medications: SSRIS

- Use with other serotonergic medications can cause Serotonin Syndrome
- Risk Category C, present in breast milk
- Rare adverse effects can be serious: Suicidal Ideation (Black Box), Bleeding, Electrolyte abnormalities
- Labs as needed for Aes, prior history

Adjunctive Treatments

- Vitamin D
- Omega 3
- Exercise
- Healthy Eating

Alternative Treatments


- SAMe – s-adenosylmethionine (Popper, 2013)
- Light Box

Alternative Treatments

- St Johns Wort – Hypericum
- Reasonable data (Popper, 2013)
- CYP Inducer → Can reduce efficacy of OCPS
- SSRI Aes


PTSD

- 17 yo Female with extensive sexual abuse history, which occurred prior to adolescence
- Presenting with nightmares, hypervigilance, hopelessness




Trauma

- Can present as PTSD
- Can be a relevant clinical factor, even if patient does not meet criteria for PTSD



Hypothetical Physiology of Trauma



Trauma


- Exposed to trauma
- 1 month or greater of the following symptom cluster
- >= 1 symptom of **Re-experiencing**,
 - Intrusive memories, nightmares, flashbacks, emotional or physiologic distress
- >= 1 symptom of **Avoidance**
 - Psychological or physical avoidance
- >= 2 **Negative cognitions**, negative moods
 - Amnesia, critical lens, negative affect, decreased interest in enjoyable activities, isolation.
- >= 2 symptoms **Hyperarousal**
 - Aggression
 - Hypervigilance

Trauma


- Trauma Focused CBT
- SSRIs for mood component
- Prazosin for nightmares, sleep, hyperarousal (Akinsanya et al., 2017)

Psychosis

- 15 year old female with a history of developmental delay,
- Presenting to clinic with paranoia, racing thoughts and poor sleep



Hypothetical Physiology of Psychosis



Schizophrenia

- ≥ 2 within a month
 - **Delusions**
 - **Hallucinations**
 - **Disorganized Speech**
 - Grossly Disorganized or Catatonic
 - Negative Symptoms
- Dysfunction for ≥ 6 Mo
- +/- Catatonia

Psychosis

- Childhood Psychosis is rare : $\sim 1/40,000$
 - Duration of Untreated Psychosis (DUP)
- Psychotic symptoms are more common
- Key Triage Question: Primary versus Other
- Treat Underlying Condition

Psychosis

- Talk with the Family
- Understand the concern
- Formulate a hypothesis
 - Use the Bio – Psycho – Social Model

Psychotic Symptoms

<p>Positive Psychotic Symptoms</p> <ul style="list-style-type: none"> Perceptions Delusion Form of thought problems <p>Disorganized symptoms</p> <ul style="list-style-type: none"> Odd behavior, appearance Bizarre thoughts Trouble with attention Personal hygiene 	<p>Negative Psychotic Symptoms</p> <ul style="list-style-type: none"> Social withdrawal or decline in function Avolition Expression of emotion problems Experiences of emotion or self problems <p style="text-align: center;">Transient symptoms</p>
--	--

Diagnostic Possibilities

- Mood Disorder with Psychosis
- Substance or Medication Induced
- Schizotypal Personality Disorder
- Primary Psychoses

Diagnostic Possibilities

- Primary Psychoses
 - Schizophrenia - Persistent
 - Schizophreniform – 6 months
 - Brief Psychotic Disorder – 1 month
 - Delusional Disorder
 - Schizoaffective Disorder

What Does Psychosis Look Like?


- Prodrome and Primary Psychoses
 - More (though not exclusively) sustained
 - Use your countertransference
 - "Odd", "things not adding up"
- Substance Induced
 - Timing!
- Mood Disorders
 - Mood Congruence

Treatment Antipsychotics

- Metabolic side effects
- Movement Side effects
 - Rarely, can be permanent
- Dangerous Side effects
 - NMS et al
- Cardiac
 - QTC

Anxiety

- 18 year old male recently enrolled in local university, "I can't get myself to school", I am too worried about what people will say about me.



Anxiety

- “Anxiety may become symptomatic at any age when it prevents or limits developmentally adaptive behaviors” (Evans et al., 2005)
- Distress + Dysfunction + Inflexibility
- Consistent patterns of
- Avoidance
- Anxiety in the absence of stimulus

Anxiety

- Talk with the Family
- Understand the concern
- Formulate a hypothesis
 - Use the Bio – Psycho – Social Model

Anxiety

- CBT
 - Anxiety scales followed by exposures targeting avoidance
- SSRIs

Anxiety

- Children > Adolescents
 - Separation Anxiety
 - Selective Mutism
- Adolescents > Children
 - Panic Disorder
 - Social Anxiety Disorder
 - Generalized Anxiety
 - Specific Phobia

Symptoms of Anxiety

- Panic Attacks
 - Abrupt occurrence of
 - Palpitations, trembling, sweating, cp, n/v, dizziness, chills, heat sensations, parasthesias, derealization / depersonalization, fear of dying or "going crazy"
- Sympathetic symptoms
- Somatic symptoms

Anxiety

- Separation anxiety
 - > 4 weeks and \geq 3 of
 - Developmentally inappropriate fear concerning separation for attachment figures
 - Persistent worry about bad things happening to attachment figures
 - Alterations in sleep, absenteeism, nightmares, somatic symptoms
 - CBT and SSRIs

Anxiety

- Selective Mutism
 - > 1 month of consistent failure to speak in certain settings, that interferes with schooling, social relationships
 - Exposures, CBT
 - SSRI

Anxiety

- Panic Disorder
 - Recurrent panic attacks
 - Fear of inducing attacks (> 1 Month)
 - Resulting change in behavior
- Treatment: CBT and SSRIs (at least 3 RCTS)

Anxiety

- Social Anxiety Disorder
 - Fear about social settings with PEERS (not just adults), out of proportion to context
 - Concern with scrutiny of others
 - CBT
 - SSRI > SNRI
 - Multiple RCTs

Anxiety

- Generalized Anxiety Disorder
 - \geq 6 mo of worry that is difficult to control and about many things
 - \geq 1
 - Restlessness, fatigue, poor concentration, irritability, muscle tension, sleep probs
- CBT
- SSRI

Anxiety

- Specific Phobia
 - > 6 Mo \rightarrow Marked fear or anxiety of a thing that is out of proportion to associated danger
 - Can be expressed by tantrums, freezing or clinging
 - Impairing
- EXPOSURES
- Data for SSRI is less convincing, but exposures work so well, that we use medication less

Depression References

*www.samhsa.gov/data/sites/default/files/Health_Equity_National_BHB_1-27-16_508.pdf

- Curtin S.C., et al (2016). "Increase in Suicide in the United States, 1999–2014". NCHS Data Brief No. 241, April 2016
- Brent, D. et al. (2008). "Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial". *JAMA* Feb 27, 2008 Vol 299, No. 8
- Hetrick SE, et al (2012). "Newer generation antidepressants for depressive disorders in children and adolescents." *Cochrane Database Syst Rev*. 2012;11:CD004851. <https://doi.org/10.1016/j.jad.2016.05.042>
- Kovacs, M., Obrosky, S., & George, C. (2016). The course of major depressive disorder from childhood to young adulthood: Recovery and recurrence in a longitudinal observational study. *Journal of Affective Disorders*, 203, 374–381. <https://doi.org/10.1016/j.jad.2016.05.042>
- Le Noury, J. et al. (2015). "Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence." *British Medical Journal* 2015, 351 doi: <http://dx.doi.org/10.1136/bmj.h4320> (Published 16 September 2015)
- March, J. et al. (2004). "Fluoxetine, Cognitive Behavioral Therapy, and Their Combination for Adolescents with Depression: Treatment for Adolescents with Depression Study (TADS) Randomized Clinical Trial". *JAMA* August 18, 2004, Vol 292, No. 7.
- Popper, CW (2013). "Mood Disorders in Youth: Exercise, Light Therapy, and Pharmacologic Complimentary and Integrative Approaches". *Child Adolesc Psychiatr Clin N Am* 22 (2013) 403–441
- Wagner, KD et al. (2003). "Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials." *JAMA*. 2003 Aug 27;290(8):1033-41.

Anxiety References

Ipsier JC., Dj. S., Hawkrigde, S., & Hoppe, L. (2010). *Pharmacotherapy for anxiety disorders in children and adolescents (Review)*. (3). doi:10.1002/14651858.CD005170.pub2.www.cochranelibrary.com

Treating and Preventing Adolescent Mental Health Disorders: What We Know and What We Don't Know: A Research Agenda for Improving the Mental Health of Our Youth. Edited by Dwight L. Evans, Edna B. Foa, Raquel E. Gur, Herbert Hendin, Charles F. O'Brien, Martin E.P. Seligman, and B. Timothy Walsh. 618 pp. New York, Oxford University Press, 2005

Strawn, J. R., Welge, J. A., Ph, D., Wehry, A. M., Keshishin, B., & Rynn, M. A. (2015). EFFICACY AND TOLERABILITY OF ANTIDEPRESSANTS IN PEDIATRIC ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. 15/7(November 2014), 149–157. doi:10.1002/da.22329

Trauma References

- Akinsanya, A., Marwaha, R., & Tampi, R. R. (2017). Prazosin in Children and Adolescents with Posttraumatic Stress Disorder Who Have Nightmares: A Systematic Review. *Journal of Clinical Psychopharmacology*, 37(1), 84–88. <https://doi.org/10.1097/JCP.0000000000000638>
- Cisler, J. M., Sigel, B. A., Kramer, T. L., Smitherman, S., Vanderzee, K., Pemberton, J., & Kilts, C. D. (2015). Amygdala response predicts trajectory of symptom reduction during Trauma-Focused Cognitive-Behavioral Therapy among adolescent girls with PTSD. *Journal of Psychiatric Research*, 71, 35–40. <https://doi.org/10.1016/j.jpsychres.2015.08.011>

Psychosis References

Gochman, P., Miller, R., & Rappoport, J. L. (2012). Childhood-Onset Schizophrenia: The Challenge of Diagnosis, 13(5), 321–322. doi:10.1007/s11920-011-0212-4. *Childhood-Onset*

Lambert, M., Ruppelt, F., Rohenkohl, A., Sengutta, M., Lueddecke, D., Nawara, L. A., ... Karow, A. (2017). Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study, 1–13. doi:10.1111/axps.12762

Pagsberg, A. K., Jeppesen, P., Klauber, D. G., Jensen, K. G., Rudå, D., Stentebjerg-lesen, M., ... Fink-jensen, A. (n.d.). Articles Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. *The Lancet Psychiatry*, 1–14. doi:10.1016/S2215-0366(17)30166-9